ESMO-The-Christie-Virtual-Preceptorship-on-Lung-Cancer-2021-1000x250px

Start date: 10 Mar 2021
End date: 12 Mar 2021
Location: Virtual, CET Time

Learning objectives

To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
To learn about the management of early stage NSCLC and use of adjuvant treatments
To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
To learn about treatment of NSCLC with oligometastatic disease
To learn about the systemic treatment of mesothelioma and SCLC

Accreditation

The programme of this virtual event has been accredited with 11 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.

Co-Chairs

Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom
Enriqueta Felip, Spain

Learning objectives

Accreditation

Co-Chairs

Supported by